Francesco Zappa
Bellinzona, TI 6500, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Neutrino Trapping and Out-of-Equilibrium Effects in Binary Neutron-Star Merger Remnants.
Journal: Physical review letters
Published: October 31, 2023
Black-Hole Remnants from Black-Hole-Neutron-Star Mergers.
Journal: Physical review letters
Published: April 11, 2019
Gravitational-Wave Luminosity of Binary Neutron Stars Mergers.
Journal: Physical review letters
Published: December 13, 2017
24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.
Journal: Journal of translational medicine
Published: November 16, 2016
Target Therapy in Lung Cancer.
Journal: Advances in experimental medicine and biology
Published: December 16, 2015
High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA).
Journal: Journal of biomedical informatics
Published: June 04, 2015
EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Journal: Clinical lung cancer
Published: May 19, 2015
Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 04, 2014
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.
Journal: PloS one
Published: March 06, 2013
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 22, 2012
Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: April 24, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026